# ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)

> **NCT03354936** · — · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 50 (estimated)

## Conditions studied

- HIV Infected Patients With Cancer Treated by ICPi

## Interventions

- **BIOLOGICAL:** Blood sample

## Key facts

- **NCT ID:** NCT03354936
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-17
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-06-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03354936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03354936, "ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03354936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*